Ask AI
H.R. 5573

PRICED Act

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Referred to the House Committee on Energy and Commerce.

Rep. Schakowsky, Janice D. [D-IL-9](D-IL)Sponsor
8 cosponsors8 D
8cosponsors1committees3actions1related bills3subjects
  1. IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  2. IntroReferralIntro-H

    Introduced in House

  3. IntroReferral1000

    Introduced in House

PRICED Act — Informed